Background: Asthma is a multidimensional disease with noticeable heterogeneity in its
presentation and reaction to treatment. Noninvasive biomarkers to determine disease
progression are highly desirable. This study sought to identify fractional exhaled nitric oxide
(FeNO), FeNO as a prognostic biomarker for asthma exacerbations, as well as a predictive
biomarker for change in other known asthma indicators. Materials and Methods: A
prospective, longitudinal study was conducted with a cohort of adult patients with severe …